Published in J Am Geriatr Soc on October 01, 2007
Recorded quality of primary care for osteoarthritis: an observational study. Br J Gen Pract (2008) 1.26
Quality indicators for the primary care of osteoarthritis: a systematic review. Ann Rheum Dis (2013) 1.01
Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults. Ann Longterm Care (2010) 0.97
CareTrack Australia: assessing the appropriateness of adult healthcare: protocol for a retrospective medical record review. BMJ Open (2012) 0.89
Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study. Consult Pharm (2008) 0.87
Personal health records: a randomized trial of effects on elder medication safety. J Am Med Inform Assoc (2013) 0.86
[Cornerstones of quality assurance in medicine in Germany : Important impulse for the situation in treatment of rheumatism]. Z Rheumatol (2016) 0.86
Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. J Am Geriatr Soc (2014) 0.77
Quality of Co-Prescribing NSAID and Gastroprotective Medications for Elders in The Netherlands and Its Association with the Electronic Medical Record. PLoS One (2015) 0.75
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2004) 4.77
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc (2006) 2.96
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2002) 2.43
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med (2009) 2.27
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med (2002) 2.01
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum (2004) 1.76
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum (2006) 1.69
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf (2006) 1.65
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Validity of gout diagnoses in administrative data. Arthritis Rheum (2007) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum (2005) 1.58
The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol (2008) 1.58
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res (2008) 1.55
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol (2003) 1.47
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol (2002) 1.46
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res (2012) 1.44
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med (2007) 1.41
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol (2003) 1.35
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care (2009) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res (2012) 1.27
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 1.26
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Treatment of rheumatoid arthritis. Am J Health Syst Pharm (2006) 1.21
Health services utilization after fractures: evidence from Medicare. J Gerontol A Biol Sci Med Sci (2010) 1.19
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005. J Bone Miner Res (2009) 1.18
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol (2005) 1.12
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10
Racial disparities in osteoporosis prevention in a managed care population. South Med J (2003) 1.10
Developing a provisional definition of flare in patients with established gout. Arthritis Rheum (2012) 1.10
Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. J Am Med Dir Assoc (2006) 1.10
Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. Curr Rheumatol Rep (2011) 1.10
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) (2012) 1.09
The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health. Contemp Clin Trials (2012) 1.09
Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum (2003) 1.07
Pathophysiology, clinical presentation and treatment of gout. Drugs (2006) 1.06
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc (2010) 1.06
Death, debility, and destitution following hip fracture. J Gerontol A Biol Sci Med Sci (2013) 1.03
Bridging the osteoporosis quality chasm. J Bone Miner Res (2009) 1.03
Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol (2006) 1.03
From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis (2010) 1.02
The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther (2010) 1.02
Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. J Natl Med Assoc (2005) 1.02
Communicating non-steroidal anti-inflammatory drug risks: verbal counseling, written medicine information, and patients' risk awareness. Patient Educ Couns (2010) 1.02
The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab (2008) 1.02
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med (2013) 1.01
The association of race/ethnicity with the receipt of traditional and alternative arthritis-specific health care. Med Care (2003) 1.01
Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior. Arthritis Rheum (2007) 1.00
Osteoporosis in the home health care setting: A window of opportunity? Arthritis Rheum (2006) 0.98
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther (2009) 0.98
Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. Nat Clin Pract Rheumatol (2008) 0.97
Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis (2011) 0.96
Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum (2013) 0.96
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2012) 0.96
Developments in glucocorticoid therapy. Rheum Dis Clin North Am (2005) 0.96
Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol (2006) 0.95
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum (2011) 0.95
The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awareness. Ann Pharmacother (2010) 0.95
Use of mainstream nonpharmacologic treatment by patients with arthritis. Arthritis Rheum (2004) 0.94
Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol (2008) 0.93
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum (2013) 0.92
Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007. J Am Pharm Assoc (2003) (2010) 0.92
Bone mineral density changes within six months of renal transplantation. Transplantation (2003) 0.91
Health-related quality of life among self-reported arthritis sufferers: effects of race/ethnicity and residence. Qual Life Res (2006) 0.91
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom (2011) 0.91